Alcon Q1 2023 Earnings Presentation
Q1 2023 Surgical
Surgical growth driven by strong consumables and
equipment sales, partially offset by
PCIOLS in South Korea
+
+
Alcon
• Increase in IOL sales across geographies (excl. South Korea);
Implantables growth +5% USD y/y excl. South Korea
• Global ATIOL penetration +90 bps y/y excl. South Korea;
Continued ATIOL global and US market leadership
• Consumables growth reflects favorable market conditions across
geographies and select price increases
Equipment sales reflect continued strong demand in international
markets for cataract and vit-ret equipment
●
$47M decrease in Implantables sales from PCIOL sales in South Korea
following a reimbursement change that took effect April 1, 2022
-400 bps of negative impact from FX on Surgical sales growth
1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix.
Net Sales
(USD $M)
$1,259
$455
$601
$203
1Q22
$1,304
$656
$427 (6%) (3%)
$221
1Q23
(USD) (CC)¹
Implantables
Consumables
Equipment/other
4% 8%
9% 13%
9%
13
14%View entire presentation